Does Argus HQ track new FDA actions for SENORES PHARMS automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to SENORES PHARMS is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for SENORES PHARMS?

1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for SENORES PHARMS?

September 22, 2026. Argus HQ ingests new FDA enforcement records daily.

Is this FDA enforcement data for SENORES PHARMS official?

Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

SENORES PHARMS — FDA Compliance Timeline

Here's the summary: Argus HQ has recorded 1 FDA events for SENORES PHARMS: 0 warning letters, 0 recalls, 1 approvals, and 0 inspection 483 observations. These events span from 2026-09-22 to 2026-09-22. The most severe rating Argus HQ has assigned across this history is "info". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	1
Form 483 inspection citations	0
Most recent action	September 22, 2026

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. SENORES PHARMS has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2026-09-22, Argus HQ recorded an FDA approval for SENORES PHARMS, rated "info" severity in Argus HQ's classification: SENORES PHARMS — ANDA approval: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

Does Argus HQ track new FDA actions for SENORES PHARMS automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to SENORES PHARMS is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for SENORES PHARMS?: 1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for SENORES PHARMS?: September 22, 2026. Argus HQ ingests new FDA enforcement records daily.
Is this FDA enforcement data for SENORES PHARMS official?: Every record links directly to its primary FDA.gov source. Argus HQ aggregates and structures public FDA data; the verbatim FDA record is always the source of truth.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

SENORES PHARMS — ANDA approval: HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE (unspecified) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Sep 22, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). SENORES PHARMS — FDA Compliance Timeline. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/senores-pharms

MLA

"SENORES PHARMS — FDA Compliance Timeline." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/senores-pharms.

Chicago

Argus HQ Research. "SENORES PHARMS — FDA Compliance Timeline." Digital Empire Holdings LLC. Accessed October 12, 2026. https://argushq.ai/company/senores-pharms.

BibTeX

@misc{argushq_argushq_ai_company_senores_pharms_2026,
  title = {SENORES PHARMS — FDA Compliance Timeline},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/senores-pharms},
  note = {Accessed: October 12, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗